Ocular complications of neurological therapy

European Journal of Neurology

Volumn 12, Issue 7, 2005, Pages 499-507

  Hadjikoutis, S ^a   Morgan, J E ^a,b   Wild, J M ^b   Smith, P E M ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Complication; Eye; Neurology; Ocular; Therapy

Indexed keywords

ACETAZOLAMIDE; AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATROPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; OXYBUTYNIN; PHENYTOIN; PROPANTHELINE BROMIDE; TOLTERODINE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROIC ACID; VIGABATRIN;

BRAIN RADIATION; CATARACT; DIPLOPIA; EYE DISEASE; EYE MALFORMATION; EYE MOVEMENT DISORDER; EYE TOXICITY; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; KERATITIS; MYOKYMIA; NYSTAGMUS; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; PRENATAL EXPOSURE; PRIORITY JOURNAL; REFRACTION ERROR; REVIEW; VISUAL FIELD DEFECT;

ACETAZOLAMIDE; ADRENAL CORTEX HORMONES; AMANTADINE; ANTICONVULSANTS; ANTITUBERCULAR AGENTS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGENTS; ETHAMBUTOL; EYE DISEASES; FEMALE; FRUCTOSE; HUMANS; ISONIAZID; MALE; RADIOTHERAPY; VIGABATRIN;

EID: 21844470270     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01025.x     Document Type: Review

References (73)

1. Arndt CF, Derambure P, Defoort-Dhellemmes S et al. (1999). Outer retinal dysfunction in patients treated with vigabatrin. Neurology 52:1201-1205.
2. Bacskulin A, Guthoff R (1999). Neuromyotonia of the abducens nerve after hypophysectomy and radiation. Strabismus 7:37-40.
3. Banta JT, Hoffman K, Budezn L et al. (2001). Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 132:112-114.
4. Bartlett JD, Jaanus SD (1989). Ocular effects of system drugs. In: Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. Stoneham, MA, Butterworth, pp. 801-842.
5. Berchou RC (1979). Carbamazepine-induced oculogyric crisis. Arch Neurol 36:522-523.
6. Berger JR, Kovacs AG (1982). Downbeat nystagmus with phenytoin. J Clin Neuroophthalmol 2:209-211.
7. Bernstein HN, Schwartz B (1962). Effects of long-term systemic steroids on ocular pressure and topographic values. Arch Ophthalmol 68:742-753.
8. Besch D, Kurtenbach A, Apfelstedt-Sylva E et al. (2002). Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151-170.
9. Black RL, Oglesby RB, Von Sallmann L et al. (1960). Posterior subcapsular cataracts induced in patients with rheumatoid arthritis. JAMA 174:166-171.
10. Campbell WW Jr (1980). Periodic alternating nystagmus in phenytoin intoxication. Arch Neurol 37:178-180.
11. Carr RE, Henkind P (1962). Ocular manifestations of ethambutol: toxic amblyopia after administration of an experimental antituberculous drug. Arch Ophthalmol 67:566-571.
12. Chrousos GA, Cowdry R, Schuelein M et al. (1987). Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine. Am J Ophthalmol 103:221-224.
13. Clarel A (1961). Retrobulbar optic neuritis during treatment with isoniazid. Bull Soc Ophthal 61:786-787.
14. Committee for Proprietary Medicinal Products (1999). Vigabatrin, European Agency for the Evaluation of Medicinal Products Report/1357/99.
15. Covell LL (1958). Glaucoma induced by systemic steroid therapy. Am J Ophthalmol 45:108-109.
16. Crompton MR, Leyton DD (1961). Delayed radionecrosis of the brain following therapeutic x-radiation of the pituitary. Brain 84:85-101.
17. Crompton J, Ravindran J, Blumbergs P et al. (2000). Vigabatrin induced visual field loss: pathological correlations. Neuroophthalmol 23:204.
18. Daneshvar H, Racette L, Coupland SG et al. (1999). Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106:1792-1798.
19. Devita EG, Miao M, Sadun AA (1987). Optic neuropathy in ethambutol-treated renal tuberculosis. J Clin Neuroophthalmol 7:77-86.
20. Eke T, Talbot JF, Lawden MC (1997). Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180-181.
21. Elliot DB, Gilchrist B, Kim JY et al. (1989). Contrast sensitivity changes with three types of cataract morphology: are these techniques necessary in a clinical evaluation of cataract? Physiol Opt 9:25-30.
22. Ezra E, Spalton D, Sanders MD (1996). Ocular neuromyotonia. Br J Ophthalmol 80:350-355.
23. Fisher RF (1987). The lens: pathology of the crystalline lens. In: Miller S, ed. Clinical Ophthalmology. Butterworth and Co. Ltd, New York, pp. 277.
24. Fraunfelder FT, Martha Meyer S (1990). Amantadine and corneal deposits. Am J Ophthalmol 110:96-97.
25. Fredericks CA, Gianotta SL, Sadun AA (1986). Dilantin-induced long-term bilateral total external ophthalmoplegia. J Clin Neuroophthalmol 6:22-26.
26. Frisen L, Malmgren K (2003). Characterisation of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466-473.
27. Garbe E, LeLorier J, Boivin JF et al. (1997). Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticosteroids. Lancet 350:979-982.
28. Garland MA, Sholk A, Guenter KE (1962). Acetazolamide induces myopia. Am J Obstet Gynecol 84:69-71.
29. Gigantelli JW, Braddock SR, Johnson LN (2000). Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embryopathy. Ophthal Plast Reconstr Surg 16:52-54.
30. Hampton GR, Krepostman JI (1981). Ocular manifestations of the fetal hydantoin syndrome. Clin Pediatr 20:475-478.
31. Harding GF, Spencer EL, Wild JM, Conway M, Bohn RL (2002). Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 58:1261-1265.
32. Hardus P, Veruin WM, Postma G et al. (2000). Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41:581-587.
33. Harsh AS, Henry SO, William BL, Lexington K (2001). Topiramate-induced acute myopia and retinal striae. Arch Ophthalmol 119:775-777.
34. Hobbs HE, Eadie SP, Sommerville F (1961). Ocular lesions after treatment with chloroquine. Br J Ophthalmol 45:284-298.
35. Jobling AL, Augusteyn C (2002). What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85:61-75.
36. Johnson MA, Krauss GL, Miller A (2000). Visual function loss from vigabatrin: effects of stopping the drug. Neurology 55:40-45.
37. Kalviainen R, Nousssiainen I, Mantyjarvi M et al. (1999). Vigabatrin, a gabaergic drug, causes concentric visual field defects. Neurology 53:922-926.
38. Klyne LB, Kim JY, Ceballos R (1985). Radiation optic neuropathy. Ophthalmology 92:1118-1126.
39. Kumar A, Sandramouli S, Verma L et al. (1993). Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol 13:15-17.
40. Lawden MC, Eke T, Degg C et al. (1999). Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716-722.
41. Leibold JE (1971). Drugs having a toxic effect on the optic nerve. Int Ophthalmol Clin 11:137-157.
42. Manuchehri K, Goodman S, Sivitel L et al. (2000). A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84:499-505.
43. McMahon CL, Braddock SR (2001). Septo-optic dysplasia as a manifestation of valproic acid embryopathy. Teratology 64:83-86.
44. Miller NR, Johnson MA, Paul SR et al. (1999). Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53:2082-2087.
45. Moore SJ, Turnpenny P, Quinn A et al. (2000). A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37:489-497.
46. Mullaly WJ (1982). Carbamazepine-induced ophthalmoplegia. Arch Neurol 34:1593-1596.
47. Murihead JF, Scheie HG (1960). Transient myopia after acetazolamide. Arch Ophthalmol 63:315-318.
48. Osborne JP, Edwards SW, Hancock E et al. (1999). Infantile spasms and vigabatrin: study will compare effects of drugs. BMJ 318:56-57.
49. Parsons JT, Bora FJ, Fitzgerald CR et al. (1994). Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Rad Oncol Biol Phys 30:755-763.
50. Petrera JE, Fledelius HC, Trojaborg W (1988). Serial pattern evoked potential recording in a case of toxic optic neuropathy due to ethambutol. Electroenceph Clin Neurophysiol 71:146-149.
51. Ponjavic V, Granse L, Andreasson S et al. (2000). Multifocal-ERG and full-field ERG in patients on vigabatrin medication. Invest Ophthalmol Vis Sci 41:242.
52. Rashbass C (1959). Barbiturate nystagmus and mechanics of visual fixation. Nature 183:897-898.
53. Remler BF, Leigh J, Osorio I, Tomsak RL (1990). The characteristics and mechanisms of visual disturbance associated with anticonvulsant therapy. Neurology 40:791-796.
54. Riker WK, Downes H, Olsen GD, Smith B (1978). Conjugate lateral gaze nystagmus and free phenytoin concentrations in plasma: lack of correlation. Epilepsia 19:93-98.
55. Ruether K, Pung T, Kellner L et al. (1998). Electrophysiologic evaluation of a patient with peripheral visual field constriction associated with vigabatrin. Arch Ophthalmol 116:817-819.
56. Salmon JF, Carmichael TR, Welsh NH (1987). Use of contrast sensitivity measurement in the detection of subclinical ethambutol toxic optic neuropathy. Br J Ophthalmol 71:192-196.
57. Sander JWAS (1998). New treatment for epilepsy. Curr Opin Neurol 11:141-148.
58. Schear MJ, Rowan AJ, Weiner JA et al. (1990). Drug-induced myopia: a transient side effect of topiramate. Epilepsia 31:643.
59. Schechter PJ, Tranier Y, Jung MJ et al. (1977). Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 45:319-328.
60. Sciefer V, Schilder J, Paetzold J, Dietrich TJ, Vonthein R, Beich D (2001). Evaluation of extensive visual field defects with computer assisted kinetic perimetry. Klin Monatsbl Angenheilkd 218:13-20 (German).
61. Sills GJ, Patsalos PN, Butler E (2000). Pharmacokinetic and pharmacodynamic profile of vigabatrin and tiagabine in rat brain and eye. 5th Eilat Conference on New Antiepileptic Drugs (25-29 June, Eilat) 61:128-134.
62. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ (2001). Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 57:196-200.
63. Siret DJ (1992). Ocular side effects of selected systemic drugs. Optom Clin 2:73-96.
64. Stefan H, Bernatik J, Knorr J (1999). Visual field defects due to antiepileptic drugs. Nervenarzt 70:552-555.
65. Sutciffe AG, Jones RB, Woodruff G (1998). Eye malformations associated with treatment with carbamazepine during pregnancy. Ophthalmic Genet 19:59-62.
66. Sutton PH, Beattie PH (1955). Optic atrophy after administration of isoniazid with PAS. Lancet 1:650-651.
67. Trier K, Olsen EB, Kobayashi T, Ribel-Madsen SM (1999). Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine. Br J Ophthalmol 83:1370-1375.
68. Tripathic RC, Parapuram SK, Zhong Y et al. (1999). Corticosteroids and glaucoma risk. Drug Aging 15:439-450.
69. Umeda Y, Sakata E (1977). Equilibrium disorder in carbamazepine toxicity. Ann Otol Rhinol Laryngol 86:318-322.
70. West J, Burke JP, Strachan I (1990). Carbamazepine, epilepsy, and optic nerve hypoplasia. Br J Ophthalmol 74:511.
71. Wild JM, Martinez C, Reinshagen G et al. (1999). Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784-1794.
72. Wilson RS, Smead W, Char F (1978). Diphenylhydantoin teratogenicity: ocular manifestations and related deformities. J Pediatr Ophthalmol Strabismus 15:137-140.
73. Woung LC, Jou JR, Liaw SL (1995). Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 11:411-419.